PARP1 and neoplasm: In SCLC, preclinical data suggest that synergy between PARP inhibitors and PD-L1 checkpoint inhibition may depend on intact tumor cell STING and innate immune activity downstream of cytosolic DNA released after PARP inhibition [64].